NCT07233720

Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

A Multicenter Prospective Real-world Study of Zanubrutinib Combined With Rituximab (ZR) in the First-line Treatment for Patients With Marginal Zone Lymphoma (MZL)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).

Conditions

• Marginal Zone Lymphoma

Interventions

Type	Name	Description
DRUG	Zanubrutinib	160mg twice daily continuous oral administration.
DRUG	Rituximab	375mg/m2, Intravenous administration on day 1 of each 3-week cycle

Timeline

• Start date: 2025-11-18
• Primary completion: 2028-06-01
• Completion: 2030-06-01
• First posted: 2025-11-18
• Last updated: 2025-11-18

Locations

1 site across 1 country: China